Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLXNASDAQ:IOVANASDAQ:PTCTNASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$67.92-0.9%$66.90$47.88▼$107.37$3.73B0.32533,783 shs95,659 shsIOVAIovance Biotherapeutics$3.64+0.1%$4.94$3.33▼$15.18$1.19B0.937.10 million shs3.15 million shsPTCTPTC Therapeutics$53.70-2.3%$50.83$24.00▼$58.38$4.23B0.66779,043 shs306,058 shsRNAAvidity Biosciences$31.77-2.4%$31.48$21.56▼$56.00$3.82B1.021.33 million shs173,895 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-2.28%-4.03%+9.35%-13.37%-2.75%IOVAIovance Biotherapeutics+5.52%+2.54%-32.02%-50.75%-74.26%PTCTPTC Therapeutics-0.58%-2.90%+9.19%+21.58%+86.79%RNAAvidity Biosciences+1.59%+5.61%+11.66%+8.14%+31.98%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.2716 of 5 stars3.61.00.00.03.52.50.0IOVAIovance Biotherapeutics4.3204 of 5 stars4.41.00.04.21.92.50.6PTCTPTC Therapeutics3.4859 of 5 stars3.31.00.04.43.30.80.0RNAAvidity Biosciences2.3366 of 5 stars4.51.00.00.02.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$108.4659.70% UpsideIOVAIovance Biotherapeutics 2.88Moderate Buy$20.25457.08% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$64.0019.18% UpsideRNAAvidity Biosciences 3.00Buy$66.69109.95% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, PTCT, RNA, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025RNAAvidity BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/17/2025RNAAvidity BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.003/17/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.00 ➝ $65.003/14/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$72.00 ➝ $78.003/13/2025RNAAvidity BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.003/12/2025RNAAvidity BiosciencesBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$72.003/11/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$41.00 ➝ $55.003/10/2025RNAAvidity BiosciencesBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $48.003/7/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$67.00 ➝ $70.003/7/2025PTCTPTC TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$55.003/7/2025RNAAvidity BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$70.00(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M34.57N/AN/A$9.97 per share6.81IOVAIovance Biotherapeutics$164.07M7.26N/AN/A$2.28 per share1.59PTCTPTC Therapeutics$806.78M5.25$2.58 per share20.80($10.85) per share-4.95RNAAvidity Biosciences$10.90M350.43N/AN/A$6.76 per share4.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$70.69M-$2.00N/AN/AN/A-25.94%-8.28%-5.21%5/8/2025 (Estimated)IOVAIovance Biotherapeutics-$444.04M-$1.30N/AN/AN/A-451.25%-58.43%-45.48%5/8/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)RNAAvidity Biosciences-$212.22M-$2.89N/AN/AN/A-2,772.45%-27.66%-24.56%5/8/2025 (Estimated)Latest IOVA, PTCT, RNA, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025N/APTCTPTC Therapeutics$0.85N/AN/AN/A$437.16 millionN/A2/27/2025Q4 2024ACLXArcellx-$0.63-$0.87-$0.24-$0.87$27.42 million$15.27 million2/27/2025Q4 2024IOVAIovance Biotherapeutics-$0.26-$0.26N/A-$0.26$72.17 million$73.69 million2/27/2025Q4 2024RNAAvidity Biosciences-$0.76-$0.80-$0.04-$0.80$1.74 million$2.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.294.29IOVAIovance BiotherapeuticsN/A4.223.90PTCTPTC TherapeuticsN/A2.102.04RNAAvidity BiosciencesN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%IOVAIovance Biotherapeutics77.03%PTCTPTC TherapeuticsN/ARNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx6.24%IOVAIovance Biotherapeutics12.10%PTCTPTC Therapeutics5.50%RNAAvidity Biosciences3.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8054.94 million50.70 millionOptionableIOVAIovance Biotherapeutics500327.88 million267.90 millionOptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableRNAAvidity Biosciences190120.21 million114.92 millionOptionableIOVA, PTCT, RNA, and ACLX HeadlinesRecent News About These CompaniesNatixis Advisors LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)March 28 at 3:40 AM | marketbeat.comThe Risk/Reward Of Avidity Biosciences And Its 2 Promising ProgramsMarch 26 at 10:17 AM | seekingalpha.comHow Is Avidity Biosciences Inc. (NASDAQ:RNA) Positioned in the Biotech Sector?March 26 at 8:46 AM | kalkinemedia.comEFG Asset Management North America Corp. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)March 26 at 5:50 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading 8.5% Higher - Time to Buy?March 25 at 4:20 PM | marketbeat.comCibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)March 25 at 3:53 AM | marketbeat.comSwiss National Bank Acquires 18,800 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)March 25 at 3:35 AM | marketbeat.com198,907 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Raymond James Financial Inc.March 25 at 3:20 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $979,632.40 in StockMarch 24, 2025 | americanbankingnews.comMagnetar Financial LLC Acquires Shares of 22,003 Avidity Biosciences, Inc. (NASDAQ:RNA)March 23, 2025 | marketbeat.comBrokerages Set Avidity Biosciences, Inc. (NASDAQ:RNA) Price Target at $66.69March 23, 2025 | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $246,461.10 in StockMarch 22, 2025 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 9,578 Shares of StockMarch 22, 2025 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 31,540 Shares of StockMarch 22, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 7,935 SharesMarch 22, 2025 | insidertrades.comIntech Investment Management LLC Increases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)March 22, 2025 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | prnewswire.comProficio Capital Partners LLC Makes New $1.76 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)March 20, 2025 | marketbeat.comPromising Early Results of Investigational Duchenne Muscular Dystrophy TherapyMarch 19, 2025 | managedhealthcareexecutive.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7.9% - Time to Sell?March 19, 2025 | marketbeat.comScotiabank Reaffirms Their Buy Rating on Avidity Biosciences (RNA)March 19, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsSuper Micro's International Presence Makes It a Winning StockBy Gabriel Osorio-Mazilli | March 17, 2025View Super Micro's International Presence Makes It a Winning Stock3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025How to Build the Ultimate Everything ETF PortfolioBy Jeffrey Neal Johnson | March 16, 2025View How to Build the Ultimate Everything ETF PortfolioModerna: 4 Key Reasons the CEO Just Bought $5M in SharesBy Jea Yu | March 11, 2025View Moderna: 4 Key Reasons the CEO Just Bought $5M in SharesIOVA, PTCT, RNA, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$67.92 -0.60 (-0.87%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Iovance Biotherapeutics NASDAQ:IOVA$3.64 +0.01 (+0.14%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.PTC Therapeutics NASDAQ:PTCT$53.70 -1.29 (-2.35%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Avidity Biosciences NASDAQ:RNA$31.77 -0.79 (-2.44%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Maybe It’s Time to Buy Some GameStop Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
